Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Adefovir Hep B Resistance Potential Shows Need For Combo Trials

Executive Summary

Gilead adefovir combination studies could address concerns about the potential for developing viral resistance with single-agent use of the drug for chronic hepatitis B, Gilead VP-Clinical Research Carol Brosgart, MD, told an FDA advisory committee Aug. 6

You may also be interested in...



Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals

Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals

Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.

Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel